my mhealth announces appointment of David Pettigrew as their new CEO.

Dr. Pettigrew has a broad and extensive experience in the digital health industry. Throughout his 17 year career, he has been responsible for managing large and complex digital health product development projects, building new organisational capabilities and for overall business delivery. He was an early pioneer in developing FDA-regulated smartphone apps. Most recently, he led Sagentia, an AIM-listed international technology and product development business, and was part of BrightInsight’s leadership team, focusing on building DTx solutions for the medtech and pharmaceutical industry. David holds a DPhil in Molecular Biophysics from the University of Oxford.
David replaces the founder Simon Bourne, who is transitioning to President and will continue to take an active interest in developing my mhealth’s next generation AI capabilities.
Bourne commented:
"When I co-founded my mhealth over 10 years ago we set out to transform healthcare using digital platforms. Back then this was through a simple website developed to support COPD patients. We never imagined back then how much this simple tool would transform the lives of patients.
Following successful randomised clinical trials and NHS National Innovation Accelerator adoption, my mhealth has supported over 80,000 patients and multiple long-term conditions across the UK. During the pandemic, we delivered access to digital rehabilitation, when most services had to close. We are also proud of the contribution we made in easing capacity pressures in the NHS through our COVID virtual ward remote monitoring solution.
Today marks an important event in our history, as I hand over the CEO role to David Pettigrew. David has a proven track record, and having worked with him over the last 5 months in his role as Chief Strategy Officer, I have every confidence he will take my mhealth to the next level."
Pettigrew stated
"Having spent 17 years developing DTx solutions, I can confidently say that no other company has been as successful as my mhealth in building such a vast and engaged user base. I would like to take this opportunity to thank Simon and the team for all their hard work to bring the company to where it is today. I’m honoured to be taking on the responsibility of leading my mhealth in the next stage of its journey, which will focus on launching in the US and beyond, expanding our relationship with the NHS and extending our data and clinical trial partnerships with the pharmaceutical industry. Our primary mission will continue to be improving the lives of patients with long term conditions everywhere."
About my mhealth
my mhealth’s digital therapeutics have been prescribed to over 80,000 patients with chronic conditions, resulting in reduced morbidity and hospital admissions. It serves patients across a range of long term conditions, including COPD, asthma, diabetes and cardiovascular disease. Our flagship product, myCOPD, was the exclusive digital therapeutic deployed by the UK’s NHS to deliver pulmonary rehabilitation during the pandemic, when in person care was practically inaccessible. Real world and clinical trial evidence demonstrates the efficacy of digital interventions on the my mhealth platform.
For more information on my mhealth, visit www.mymhealth.com.

Your Feedback, Our Improvements We want to make sure our product is designed with your needs in mind. To achieve this, we regularly send out surveys and work closely with our Patient & Public Involvement (PPI) group, ensuring that your feedback directly shapes improvements and updates. We received 147 responses to our Research Community Survey .. said they found our app easy to use Overall, most of you said you had positive experiences of using the app .. said you would keep using it to manage your condition Our PPI activities have helped us to make important changes... Navigating around isn’t always that easy The home screen menu is now grouped into smaller sections with a ‘To Do’ list to help you stay on track Too many questions at the start makes it just too complicated Most of the questions at the start have now been removed so you can get started sooner We have now expanded the nutrition information which also contains a nutrition questionnaire to provide you with personalised advice There is not enough information on nutrition. Sometimes I forget to eat What we are working on We are creating a ‘Prepare for Your Appointment’ function in myCOPD and myAsthma We are planning to include a ‘Search’ function so you can get to what you need quickly Keep talking to us! Your experiences help us continue to improve.If you would like to share your thoughts or be part of our Patient and Public Involvement group, please join the Research Community. We would love to hear from you

A new partnership between leading digital health innovators, my mhealth and Patients Know Best (PKB) means shared NHS customers can streamline the delivery of their digital care tools, making it easier to empower patients to manage their health effectively. The collaboration brings together my mhealth’s award-winning self-management platforms with PKB’s personal health record solution, which is already embedded within the NHS App. “At the heart of this partnership is the patient,” said Dr. David Pettigrew, CEO of my mhealth . “By aligning our platforms, we’re enabling people to take greater control of their health while supporting clinicians with joined-up, efficient care pathways. It’s a significant step towards the NHS’s vision of a single ‘front door’ for digital health.” Key Benefits for Patients and the NHS: ● One seamless journey: Patients and clinicians benefit from a more unified experience across apps and services. ● Better outcomes through joined-up care: Shared access to data empowers more personalised and timely interventions. ● Greater access to services: Patients can engage with support tools and resources anytime, anywhere. ● Reduced clinical workload: Digitally enhanced care pathways streamline processes and free up clinical time. ● Scalable long-term condition support: Proven tools for managing COPD, asthma, diabetes, and more, integrated with national systems. ● Patient empowerment: Enabling people to be active participants in their health journey. This partnership also honours the early vision of digital health pioneer Dr Warner Slack, who said in the 1970s: “I hoped that the computer would help the doctor in the care of the patient. And in the back of my mind was the idea that the computer might actually help patients to help themselves with their medical problems.” Today , that vision is becoming reality - placing digital tools directly in the hands of patients and enabling a more connected, compassionate, and sustainable NHS. About my mhealth my mhealth provides evidence-based digital therapeutics for patients with long-term conditions including COPD, asthma, diabetes, and heart disease. Trusted by NHS organisations across the UK, their platforms deliver scalable self-management support and remote monitoring tools that improve outcomes and reduce healthcare burden. About Patients Know Best Patients Know Best is the World’s largest Personal Health Record (PHR) and patient engagement platform, integrating data feeds from over 550 health organisations and providers. The system connects information from GPs, hospitals, social and mental health care providers, to create a single, unified copy of patient data. Everything from appointments and letters to test results, care plans, real-time monitoring data and discharge summaries, as well as the patient’s own data, are all available in one patient record, enabling patients and healthcare professionals to access up-to-date health information anytime, anywhere. In the UK, the platform serves over 5 million patients, registering 100,000+ patients and releasing over 20 million test results a month. PKB integrates with the NHS App to provide a single front door for patients to access their information.

NHS University College London Hospitals NHS Foundation Trust, part of North Central London ICB, is taking a significant step towards enhancing patient empowerment and optimising disease management. Asthma is a chronic condition that affects millions of people worldwide, often leading to severe health complications if not managed properly. Recognising the critical need for effective self-management tools, NHS University College London Hospitals NHS Foundation Trust has chosen the myAsthma app to provide patients with the resources they need to take control of their health. Dr Kay Roy PhD FRCP, Consultant Respiratory Physician University College London Hospitals NHS Foundation Trust, comments “We are thrilled to introduce myAsthma as a self-management tool to our community. It represents a significant step forward in empowering our patients with asthma to take control of their health. By providing them with personalised support, we believe this tool will greatly improve their quality of life. Additionally, the use of myAsthma in outpatient settings will help triage patients more effectively, ensuring they are seen in a timely manner and appropriately referred for the right investigations and services. Our team is excited to see the positive impact this will have on the asthma population across North Central London ICB." The myAsthma app, part of the my mhealth suite of digital health solutions, is designed to empower patients with comprehensive tools and information to manage their asthma more effectively. Key features include: • Personalised Action Plans: Tailored asthma management plans based on individual patient needs. • Inhaler technique training: Contributing to better health outcomes and reduced risk of exacerbations • Medication Tracking: Reminders and logs to ensure patients take their medication as prescribed. • Symptom tracking: Easy-to-use tools for tracking symptoms and triggers. • Educational Resources: Access to a wealth of information on asthma, helping patients understand their condition and how to manage it. As more NHS partners embrace the my mhealth platform, we're thrilled to witness its growing impact and the positive changes it is bringing to long-term condition care. For more information on this article or other my mhealth projects, please get in touch https://mymhealth.com/contact-us
Henry M.G. Glyde1Alison M. Blythin2 Tom M.A. Wilkinson3Ian T. Nabney4 James W. Dodd5 EPSRC Centre for Doctoral Training in Digital Health and Care, University of Bristol, Bristol, UK my mHealth Limited, Bournemouth , UK my mHealth and Clinical and Experimental Science, University of Southampton, Southampton, UK School of Engineering Mathematics and Technology, University of Bristol, Bristol, UK Academic Respiratory Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK Abstract Background Acute exacerbations of COPD (AECOPD) are episodes of breathlessness, cough and sputum which are associated with the risk of hospitalisation, progressive lung function decline and death. They are often missed or diagnosed late . Accurate timely intervention can improve these poor outcomes. Digital tools can be used to capture symptoms and other clinical data in COPD. This study aims to apply machine learning to the largest available real-world digital dataset to identify AECOPD Prediction tool which could be used to support early intervention improve clinical outcomes. Objective To create and validate a machine learning predictive model that forecasts exacerbations of COPD 1-8 days in advance. The model is based on routine patient-entered data from myCOPD self-management app. Method Adaptations of the AdaBoost algorithm were employed as machine learning approaches. The dataset included 506 patients users between 2017-2021. 55,066 app records were available for stable COPD event labels and 1,263 records of AECOPD event labels. The data used for training the model included COPD assessment test (CAT) scores, symptom scores, smoking history, and previous exacerbation frequency. All exacerbation records used in the model were confined to the 1-8 days preceding a self-reported exacerbation event. Results TheEasyEnsemble Classifier resulted in a Sensitivity of 67.0% and a Specificity of 65% with a positive predictive value (PPV) of 5.0% and a negative predictive value (NPV) of 98.9%. An AdaBoost model with a cost-sensitive decision tree resulted in a a Sensitivity of 35.0% and a Specificity of 89.0% with a PPV of 7.08% and NPV of 98.3%. Conclusion This preliminary analysis demonstrates that machine learning approaches to real-world data from a widely deployed digital therapeutic has the potential to predict AECOPD and can be used to confidently exclude the risk of exacerbations of COPD within the next 8 days. Permission to use received from Henry Glyde. Read more on Heliyon website.
Charlotte Smith 1 Francesca D’angelo 2 University Hospital of Derby and Burton, Cardiac Rehabilitation Department, Burton Upon Trent, UK. University Hospital of Derby and Burton, Health and Wellbeing Department, Burton, UK To examine the effectiveness of physical activity outcomes using a web-based Cardiac Rehabilitation application compared with a conventional programme or a combination of both. University Hospitals of Derby and Burton NHS Foundation Trust poster presented at the BACPR Annual Conference October 5-6th 2023 Permission to use received from Charlotte Smith
Francesca D’angelo 1 Charlotte Smith 2 University Hospital of Derby and Burton, Health and Wellbeing Department, Burton, UK University Hospital of Derby and Burton, Cardiac Rehabilitation Department, Burton Upon Trent, UK. To examine the effectiveness of psychological outcomes using a web-based Cardiac Rehabilitation application compared with a conventional programme or a combination of both. University Hospitals of Derby and Burton NHS Foundation Trust poster presented at the BACPR Annual Conference October 5-6th 2023 Poster presented at the BACPR Annual Conference October 5-6th 2023 Permission to use received from Charlotte Smith




